1-10 of 10
Thomas Höfer
Close
Sort by
Journal Articles

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy

Johannes Sam, Thomas Hofer, Christine Kuettel, Christina Claus, Jenny Thom, Sylvia Herter, Guy Georges, Koorosh Korfi, Martin Lechmann, Miro Julian Eigenmann, Daniel Marbach, Candice Jamois, Katharina Lechner, Sreenath M. Krishnan, Brenda Gaillard, Joana Marinho, Sven Kronenberg, Leo Kunz, Sabine Wilson, Stefanie Briner, Samuel Gebhardt, Ahmet Varol, Birte Appelt, Valeria Nicolini, Dario Speziale, Miriam Bez, Esther Bommer, Jan Eckmann, Carina Hage, Florian Limani, Silvia Jenni, Anne Schoenle, Marine Le Clech, Jean-Baptiste Pierre Vallier, Sara Colombetti, Marina Bacac, Stephan Gasser, Christian Klein, Pablo Umaña
Journal: Blood
Blood (2024) 143 (21): 2152–2165.
https://doi.org/10.1182/blood.2023023381
Published: 2024
Includes: Supplemental data
Journal Articles

RG6333 (CD19-CD28), a CD19-Targeted Affinity-Optimized CD28 Bispecific Antibody, Enhances and Prolongs the Anti-Tumor Activity of Glofitamab (CD20-TCB) in Preclinical Models

Johannes Sam, Thomas Hofer, Christine Kuettel, Christina Claus, Sylvia Herter, Guy Georges, Jenny Tosca Thom, Leo Kunz, Samuel Gebhardt, Florian Limani, Stefanie Briner, Silvia Jenni, Anne Schönle, Marine Le Clech, Ahmet Varol, Esther Bommer, Birte Appelt, Sara Colombetti, Stephan Gasser, Marina Bacac, Christian Klein, Pablo Umana
Journal: Blood
Blood (2022) 140 (Supplement 1): 3142–3143.
https://doi.org/10.1182/blood-2022-159941
Published: 2022
Journal Articles

Dynamics of Clonal Hematopoiesis Inferred By Modelling Deep Bulk Whole-Genome Sequencing Data at a Single Time Point

Naser Ansari-Pour, Verena Körber, Niels Asger Jakobsen, Rachel Moore, Nina Claudino, Marlen Metzner, Batchimeg Usukhbayar, Mirian Angulo Salazar, Simon Newman, Benjamin Kendrick, Adrian Taylor, Rasheed Afinowi-Luitz, Roger Gundle, Bridget Watkins, Kim Wheway, Debra Beazley, Andrew Carr, Paresh Vyas, Thomas Höfer
Journal: Blood
Blood (2022) 140 (Supplement 1): 5753–5754.
https://doi.org/10.1182/blood-2022-166236
Published: 2022
Journal Articles

Modelling Single Cell B-Cell Receptor Signaling Reveals Enhanced Activity in Primary CLL Cells Compared to Non-Malignant Cells While Fundamental Network Circuit Topology Remains Stable Even with Novel Therapeutic Inhibitors

Daniel Mertens, PhD, Christine Wolf, PhD, Carsten Maus, PhD, Michael Persicke, Katharina Filarsky, PhD, Hartmut Döhner, Peter Lichter, PhD, Thomas Höfer, PhD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4275.
https://doi.org/10.1182/blood-2019-127837
Published: 2019
Journal Articles

Prospective isolation of nonhematopoietic cells of the niche and their differential molecular interactions with HSCs

Nicole Mende, Adrien Jolly, Gulce I. Percin, Marko Günther, Maria Rostovskaya, Shyam M. Krishnan, Robert A. J. Oostendorp, Andreas Dahl, Konstantinos Anastassiadis, Thomas Höfer, Claudia Waskow
Journal: Blood
Blood (2019) 134 (15): 1214–1226.
https://doi.org/10.1182/blood.2019000176
Published: 2019
Includes: Supplemental data
Journal Articles

GVHD Is Sustained By T Cell Maintenance within Target Tissues: Insights from Clonal Tracking and Parabiosis

Faruk Sacirbegovic, PhD, Sarah T Rosenberger, MS, Daqiang Zhao, MD PhD, Matthias Günther, PhD, Martin H Oberbarnscheidt, MD PhD, Fadi G Lakkis, MD, Thomas Höfer, PhD, Warren D Shlomchik, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 809.
https://doi.org/10.1182/blood-2018-99-119134
Published: 2018
Journal Articles

Differentiation-based model of hematopoietic stem cell functions and lineage pathways

Thomas Höfer, Hans-Reimer Rodewald
Journal: Blood
Blood (2018) 132 (11): 1106–1113.
https://doi.org/10.1182/blood-2018-03-791517
Published: 2018
Journal Articles

SETD1A protects HSCs from activation-induced functional decline in vivo

Kathrin Arndt, Andrea Kranz, Juliane Fohgrub, Adrien Jolly, Anita S. Bledau, Michela Di Virgilio, Mathias Lesche, Andreas Dahl, Thomas Höfer, A. Francis Stewart, Claudia Waskow
Journal: Blood
Blood (2018) 131 (12): 1311–1324.
https://doi.org/10.1182/blood-2017-09-806844
Published: 2018
Includes: Supplemental data
Journal Articles

Novel Tumor-Targeted, Engineered IL-2 Variant (IL2v)-Based Immunocytokines For Immunotherapy Of Cancer

Christian Klein, PhD, Inja Waldhauer, PhD, Valeria Nicolini, PhD, Claire Dunn, PhD, Anne Freimoser-Grundschober, PhD, Gerrits Danny, PhD, Otto Boerman, PhD, Tapan Nayak, PhD, Sylvia Herter, PhD, Erwin Van Puijenbroek, Oliver Ast, PhD, Thomas Hofer, PhD, Ralf Hosse, Sabine Lang, Sebastian Neumann, Hubert Kettenberger, Markus Neubauer, Ingo Gorr, Dietrich Tuerck, Stefan Evers, Christian Gerdes, Victor Levitsky, Marina Bacac, Ekkehard Moessner, Pablo Umana, PhD
Journal: Blood
Blood (2013) 122 (21): 2278.
https://doi.org/10.1182/blood.V122.21.2278.2278
Published: 2013
Journal Articles

Hypoxic up-regulation of erythroid 5-aminolevulinate synthase

Brief Report
Thomas Hofer, Roland H. Wenger, Marianne F. Kramer, Gloria C. Ferreira, Max Gassmann
Journal: Blood
Blood (2003) 101 (1): 348–350.
https://doi.org/10.1182/blood-2002-03-0773
Published: 2003